1 – 20 of 20
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE) : Protocol for a Translational Study
(
- Contribution to journal › Article
- 2023
-
Mark
Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma
(
- Contribution to journal › Article
- 2019
-
Mark
Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies
(
- Contribution to journal › Article
- 2018
-
Mark
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
(
- Contribution to journal › Article
-
Mark
Target Genes of WT1 in Leukemic Cells
2018) Scientific Symposium -European Academy for Biomedical Science(
- Contribution to conference › Poster
- 2017
-
Mark
Distinct global binding patterns of the Wilms' tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells
(
- Contribution to journal › Article
-
Mark
Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells
(
- Contribution to journal › Article
-
Mark
The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo
(
- Contribution to journal › Article
-
Mark
The transcriptional coregulator NAB2 is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells
(
- Contribution to journal › Article
- 2016
-
Mark
The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.
(
- Contribution to journal › Article
- 2015
-
Mark
Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
(
- Contribution to journal › Article
- 2013
-
Mark
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
(
- Contribution to journal › Article
- 2012
-
Mark
The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of eIF4E to eIF4G.
(
- Contribution to journal › Article
- 2011
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase.
(
- Contribution to journal › Article
- 2008
-
Mark
Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
(
- Contribution to journal › Article
- 2007
-
Mark
Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow.
2007) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 31(7). p.995-1001(
- Contribution to journal › Article
-
Mark
Regulation of the interferon-inducible p53 target gene TRIM22 (Staf50) in human T lymphocyte activation
(
- Contribution to journal › Article
- 2004
-
Mark
Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells.
(
- Contribution to journal › Article
- 2001
-
Mark
How can p53 induce differentiation of leukemic cells?
2001)(
- Thesis › Doctoral thesis (compilation)